A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer

被引：1
|
作者：
Lynce, Filipa
Yeh, Eren D.
Regan, Meredith M.
Qin, Lei
Bay, Camden P.
Krop, Ian
Harrison, Beth T.
Nakhlis, Faina
Bellon, Jennifer
Overmoyer, Beth
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P2-12-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-12-18
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Systemic Therapy of HR-positive, HER2-negative metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (03) : 257 - 257
  • [22] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1176 - 1177
  • [23] Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel (WP) or eribulin (E) followed by doxorubicin and cyclophosphamide (AC) in women with locally advanced HER2-negative breast cancer (LABC): NSABP FB-9
    Abraham, Jame
    Robidoux, Andre
    Tan, Antoinette R.
    Buyse, Marc E.
    Wolmark, Norman
    Jacobs, Samuel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] A retrospective comparison of eribulin and capecitabine in patients with HER2-negative metastatic breast cancer
    Tsushita, N.
    Shimoi, T.
    Okuma, H. S.
    Kawachi, A.
    Kitano, A.
    Nishikawa, T.
    Shimomura, A.
    Noguchi, E.
    Kodaira, M.
    Yunokawa, M.
    Yonemori, K.
    Shimizu, C.
    Fujiwara, Y.
    Tamura, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [25] Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer
    Gonzalez-Angulo, Ana M.
    Lei, Xiudong
    Alvarez, Richardo H.
    Green, Majorie C.
    Murray, James L.
    Valero, Vicente
    Koenig, Kimberly B.
    Ibrahim, Nuhad K.
    Litton, Jennifer K.
    Nair, Lakshmy
    Krishnamurthy, Savitri
    Hortobagyi, Gabriel N.
    Meric-Bemstarn, Funda
    CLINICAL BREAST CANCER, 2015, 15 (05) : 325 - 331
  • [26] A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)
    Fukada, Ippei
    Ito, Yoshinori
    Kondo, Naoto
    Ohtani, Shoichiro
    Hattori, Masaya
    Tokunaga, Eriko
    Matsunami, Nobuki
    Mashino, Kohjiro
    Kosaka, Taijiro
    Tanabe, Masahiko
    Yotsumoto, Daisuke
    Yamanouchi, Kosho
    Sawaki, Masataka
    Kashiwaba, Masahiro
    Kawabata, Hidetaka
    Kuroi, Katsumasa
    Morita, Satoshi
    Ohno, Shinji
    Toi, Masakazu
    Masuda, Norikazu
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (03) : 425 - 434
  • [27] A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)
    Ippei Fukada
    Yoshinori Ito
    Naoto Kondo
    Shoichiro Ohtani
    Masaya Hattori
    Eriko Tokunaga
    Nobuki Matsunami
    Kohjiro Mashino
    Taijiro Kosaka
    Masahiko Tanabe
    Daisuke Yotsumoto
    Kosho Yamanouchi
    Masataka Sawaki
    Masahiro Kashiwaba
    Hidetaka Kawabata
    Katsumasa Kuroi
    Satoshi Morita
    Shinji Ohno
    Masakazu Toi
    Norikazu Masuda
    Breast Cancer Research and Treatment, 2021, 190 : 425 - 434
  • [28] A phase I study of neoadjuvant chemotherapy with nanoparticle albumin-bound paclitaxel, doxorubicin, and cyclophosphamide (NAC) in patients with stages II-III HER2-negative breast cancer
    Khong, H. T.
    Dyess, D. L.
    Butler, T. W.
    Dumlao, T. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors?
    Landmann, Alessandra
    Farrugia, Daniel J.
    Diego, Emilia
    Bonaventura, Marguerite
    Soran, Atilla
    Johnson, Ronald
    Dabbs, David J.
    Clark, Beth
    Brufsky, Adam
    Davidson, Nancy E.
    Lembersky, Barry C.
    Jankowitz, Rachel Catherine
    Puhalla, Shannon
    Ahrendt, Gretchen M.
    McAuliffe, Priscilla F.
    Bhargava, Rohit
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Feasibility Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (150 mg/m2) Followed by Fluorouracil, Epirubicin, and Cyclophosphamide Therapy as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer
    Kojima, Yasuyuki
    Kawamoto, Hisanori
    Nishikawa, Toru
    Hayami, Ryosuke
    Shimo, Arata
    Haku, Ei
    Akiyama, Kyoko
    Tsugawa, Koichiro
    CLINICAL BREAST CANCER, 2018, 18 (05) : 374 - 379
12345